STOCK TITAN
  1. Home
  2. News
  3. CDXC

Chromadex Corp - CDXC STOCK NEWS

Welcome to our dedicated news page for Chromadex (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chromadex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chromadex's position in the market.

News
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will report its first quarter 2024 financial results on May 8, 2024. The company specializes in NAD+ and healthy aging research. An investor conference call will be held to discuss the results and provide a business update. The call will take place at 4:30 p.m. ET on May 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the major grocery debut of Tru Niagen® at Sprouts Farmers Market, expanding its reach to health-conscious consumers in over 400 locations across 23 states. Tru Niagen®, the top NAD+ supplement for healthy aging in the US, is now available at Sprouts, showcasing ChromaDex's commitment to enhancing access to its products. The partnership with Sprouts aligns with ChromaDex's goal of transforming the aging process for a broader audience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
Rhea-AI Summary
ChromaDex Corp. announces that its Tru Niagen product line is now third-party verified through the Alkemist Assured program, ensuring quality and transparency in the dietary supplement industry. The company's commitment to excellence and consumer trust is reinforced by this partnership, setting a new industry standard for product verification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
News
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) reported strong financial results for the fourth quarter and full year 2023, with net sales of $21.2 million and $83.6 million, respectively. The company achieved positive net income, gross margin improvements, and positive adjusted EBITDA. Key highlights include the launch of Tru Niagen® Pro 1,000 mg and successful clinical trials showcasing the benefits of Niagen® in various health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
earnings
-
News
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
Rhea-AI Summary
ChromaDex Corp. (CDXC) schedules a conference call to discuss fourth-quarter 2023 financial results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
conferences earnings
-
News
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will participate in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series on Monday, February 12, 2024, at 11:00 AM PST. The event will feature the latest investor presentation by CEO Rob Fried and CFO Brianna Gerber, followed by a live Q&A. Registration is limited, but the replay will be available on ChromaDex’s website. For more information, visit www.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
News
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) CEO and CFO will be participating in the Lytham Partners 2024 Investor Select Conference for virtual one-on-one meetings. The event is scheduled for Thursday, February 1, 2024. For more information, visit www.chromadex.com and www.investors.chromadex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announces the launch of Tru Niagen, its patented nicotinamide riboside (NR) supplement, to support the US Military Special Operations Forces. The initiative includes an exclusive program that offers Tru Niagen products to active and veteran Military Service Members, reflecting ChromaDex's commitment to the health and well-being of those who serve the Nation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
-
News
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
Rhea-AI Summary
Neurohacker Collective has launched Qualia NAD+ featuring ChromaDex's patented Nicotinamide Riboside (NR) as an NAD+ supplement to boost NAD+ levels in aging Americans. The pilot study resulted in 95% of participants rating the experience as 'excellent' to 'good.' Qualia NAD+ is positioned to become a category leader in NAD+ supplementation, leveraging Niagen, the FDA-notified form of NR, backed by two Nobel Prize winners and over 25 human clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
partnership
News
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) shares results from a new study on the safety and benefits of high-dose nicotinamide riboside (NR) supplementation for individuals with Parkinson’s disease. The study demonstrated that supplementing individuals with PD with high-dose Niagen NR was short-term safe, greatly increased whole blood NAD+ levels, and was associated with a significant clinical improvement. This marks a milestone as the first-ever clinical study to demonstrate the safety, tolerability, and beneficial effects of high-dose Niagen NR at 3,000 mg per day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
clinical trial
Stock CDXC logo
Chromadex Corp

Nasdaq:CDXC

CDXC Rankings

#3556 Ranked by Market Cap
#2909 Ranked by Stock Gains
N/A Ranked by Dividends

CDXC Stock Data

289.94M
51.40M
41.19%
16.13%
1.75%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Los Angeles

About CDXC

chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).